GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » InnoCan Pharma Corp (XCNQ:INNO) » Definitions » Cash Conversion Cycle

InnoCan Pharma (XCNQ:INNO) Cash Conversion Cycle : 226.79 (As of Dec. 2023)


View and export this data going back to 2019. Start your Free Trial

What is InnoCan Pharma Cash Conversion Cycle?

Cash Conversion Cycle is one of several measures of management effectiveness. It equals Days Sales Outstanding + Days Inventory - Days Payable.

InnoCan Pharma's Days Sales Outstanding for the three months ended in Dec. 2023 was 0.35.
InnoCan Pharma's Days Inventory for the three months ended in Dec. 2023 was 260.29.
InnoCan Pharma's Days Payable for the three months ended in Dec. 2023 was 33.85.
Therefore, InnoCan Pharma's Cash Conversion Cycle (CCC) for the three months ended in Dec. 2023 was 226.79.


InnoCan Pharma Cash Conversion Cycle Historical Data

The historical data trend for InnoCan Pharma's Cash Conversion Cycle can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

InnoCan Pharma Cash Conversion Cycle Chart

InnoCan Pharma Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cash Conversion Cycle
Get a 7-Day Free Trial - 12,002.42 880.74 594.19 292.25

InnoCan Pharma Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cash Conversion Cycle Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2,497.43 486.09 222.38 279.94 226.79

Competitive Comparison of InnoCan Pharma's Cash Conversion Cycle

For the Drug Manufacturers - Specialty & Generic subindustry, InnoCan Pharma's Cash Conversion Cycle, along with its competitors' market caps and Cash Conversion Cycle data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


InnoCan Pharma's Cash Conversion Cycle Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, InnoCan Pharma's Cash Conversion Cycle distribution charts can be found below:

* The bar in red indicates where InnoCan Pharma's Cash Conversion Cycle falls into.



InnoCan Pharma Cash Conversion Cycle Calculation

Cash Conversion Cycle (CCC) measures how fast a company can convert cash on hand into even more cash on hand. This metric looks at the amount of time needed to sell inventory, the amount of time needed to collect receivables and the length of time the company is afforded to pay its bills without incurring penalties.

Cash Conversion Cycle is one of several measures of management effectiveness.

InnoCan Pharma's Cash Conversion Cycle for the fiscal year that ended in Dec. 2023 is calculated as

Cash Conversion Cycle=Days Sales Outstanding +Days Inventory-Days Payable
=0.43+314.43-22.61
=292.25

InnoCan Pharma's Cash Conversion Cycle for the quarter that ended in Dec. 2023 is calculated as:

Cash Conversion Cycle=Days Sales Outstanding+Days Inventory-Days Payable
=0.35+260.29-33.85
=226.79

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


InnoCan Pharma  (XCNQ:INNO) Cash Conversion Cycle Explanation

Generally, the lower this number is, the better for the company. Although it should be combined with other metrics (such as ROE % and ROA %), it can be especially useful for comparing close competitors, because the company with the lowest CCC is often the one with better management.


Be Aware

CCC is most effective with retail-type companies, which have inventories that are sold to customers. Consulting businesses, software companies and insurance companies are all examples of companies for whom this metric is meaningless.

The CCC is one of several tools that can help you evaluate management, especially if it is calculated for several consecutive time periods and for several competitors. Decreasing or steady CCCs are good, while rising ones should motivate you to dig a bit deeper.


InnoCan Pharma Cash Conversion Cycle Related Terms

Thank you for viewing the detailed overview of InnoCan Pharma's Cash Conversion Cycle provided by GuruFocus.com. Please click on the following links to see related term pages.


InnoCan Pharma (XCNQ:INNO) Business Description

Traded in Other Exchanges
Address
1015, 926 - 5 Avenue SW, Calgary, AB, CAN, T2P 0N7
InnoCan Pharma Corp is a pharmaceutical tech company that focuses on the development of several drug delivery platforms combining cannabidiol with other pharmaceutical ingredients as well as the development and sale of CBD-integrated pharmaceuticals. Geographically, it derives a majority of its revenue from the United States.

InnoCan Pharma (XCNQ:INNO) Headlines

From GuruFocus

Innocap, Inc. Year End Message To Shareholders

By PRNewswire PRNewswire 12-14-2020

President of Innocap, Inc. is in Singapore

By GlobeNewswire GlobeNewswire 05-03-2018

Innocap, Inc.'s Current Activities

By Marketwired Marketwired 05-24-2018

President of Innocap, Inc. is in Singapore

By Marketwired Marketwired 05-03-2018